EMA investigates Covid-19 drug Paxlovid

Friday, 11/19/2021 5:56 PM by


| Views: 25

A scientist during an investigation. (Icon image) © Stas_Uvarov / iStock / Getty Images Plus / Getty Images

AMSTERDAM (dpa-AFX) – The European Medicines Agency EMA started an investigation of the Covid-19 drug Paxlovid from the manufacturer Pfizer started in order to enable countries to use it at an early stage even before market approval. The EMA announced on Friday in Amsterdam that existing data from tests with paxlovid in sick people at risk of a severe course would be evaluated. Preliminary results indicated that paxlovid reduced the risk of hospital treatment or a fatal outcome from corona infection. Data on the quality and safety of the drug would also be examined.

Pfizer has just filed for emergency approval for paxlovid in the United States. According to the company from the beginning of November, the corona pill is very successful in preventing serious illnesses in high-risk patients. An interim analysis of test results found the drug reduced the risk of hospital admissions and death in Covid-19 patients by 89 percent, according to Pfizer.

As the EMA explained, the investigation that is now under way is intended to enable health authorities in the EU countries to use the drug at short notice before the drug is approved. There are currently three drugs approved for the treatment of Covid patients in the EU. Applications for approval have been made for a further four in total./evs/DP/ngu


Subscribe for more news on the price of Brent Crude Oil for free

ARIVA.DE publishes analyzes, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that has been recognized by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” mark below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Other users were also interested in this article:

Leave A Comment